secwatch.observer — SEC 8-K summary
======================================

Issuer:     Insight Molecular Diagnostics Inc. (IMDX)
CIK:        0001642380
Form:       8-K
Filed at:   2024-05-23T23:59:59+00:00
Accession:  0001493152-24-021144
Event type: leadership
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Oncocyte enters employment agreement with CSO; base salary $351,525
-------------------------------------------------------------------

- Employment agreement with Chief Science Officer Ekkehard Schütz effective May 20, 2024; four-year term.
- Base salary of $351,525.20; eligible for annual cash bonus of 50% of base salary.
- Severance upon termination without cause or good reason includes 12 months base salary, pro-rata bonus, health coverage, and accelerated equity vesting.
- Agreement replaces prior Managing Director Service Agreement with Chronix Biomedical GmbH.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1642380/000149315224021144/0001493152-24-021144-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1642380/000149315224021144/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-021144

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer